Aspeya, Inc.
Clinical trials sponsored by Aspeya, Inc., explained in plain language.
-
New inhaled asthma drug begins first human safety trial
Symptom relief Recruiting nowThis early-stage trial tests a single inhaled dose of ASY202, a drug containing dihydroergotamine, in 40 adults with stable asthma. The study is randomized and placebo-controlled, meaning some participants get the drug and some get an inactive powder. The main goal is to check sa…
Phase: PHASE1 • Sponsor: Aspeya, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Inhaled powder could offer rapid migraine relief without needles
Symptom relief Recruiting nowThis study tests an investigational inhaled medication called ASY202 (dihydroergotamine dry powder) for treating migraine attacks in adults. Participants use a handheld inhaler to take the drug or a placebo during separate migraine episodes, and neither they nor the study team kn…
Phase: PHASE2 • Sponsor: Aspeya, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC